Localized insulin allergy treated with continuous subcutaneous insulin

Pratt, Edward John; Miles, Pat; Kerr, David

doi:10.1046/j.1464-5491.2001.00454-2.x

Cited by 29 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is not the first description of the use of CSII to treat localised insulin allergy in patients with either type 1 or type 2 diabetes, [2][3][4][5][6] and our patient's symptoms were significantly and sufficiently improved rather than cured. However, we are not aware of other examples where i-Port Advance™, a device that has been developed to make it possible for people with needle phobia to be able to inject insulin themselves, has been used for this indication.…”

Section: Discussioncontrasting

confidence: 56%

Desensitisation to subcutaneous insulin using CSII followed by i-Port Advance™

et al. 2017

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 56%

Desensitisation to subcutaneous insulin using CSII followed by i-Port Advance™

et al. 2017

View full text Add to dashboard Cite

“…In a 79-year-old man with a 28-year history of type 2 diabetes, the allergic reactions appeared to be variable in size and duration [68]. Three months after starting CSII with insulin lispro there has been no sign of an allergic response with successful reduction in HbA 1c levels.…”

Section: Csii With Insulin Analogues and Insulin Allergymentioning

confidence: 97%

Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues

Radermecker

Scheen

2007

Diabetes Metabolism Res

112

113

View full text Add to dashboard Cite

SUMMARYThe purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence but not completely suppressed the occurrence of insulin allergy manifestations. Advances in technologies concerning the mode of delivery of insulin, i.e. continuous subcutaneous insulin infusion (CSII), and the use of insulin analogues, resulting from the alteration in the amino acid sequence of the native insulin molecule, may influence the immunogenicity and antigenicity of native insulin. Instead of increasing allergy reactions, CSII has been reported to represent a successful alternative treatment in diabetic patients presenting local or generalized allergy to insulin or other components (zinc, protamine) of conventional treatment. Most recent reports concern CSII-treated patients using short-acting insulin analogues (essentially insulin lispro), although the precise role of these insulin analogues remains unclear as allergy to 1 them has also been described. Finally, data on antigenicity and immunogenicity of long-acting insulin analogues (glargine, detemir), which may mimic the basal insulin delivery with CSII, remain scarce at present time.

show abstract

“…Since most desensitization protocols involve starting insulin administration with very small amounts and gradually increasing the amount of insulin to therapeutic levels, the use of CSII in patients with insulin allergy seems to be conceivable. Several cases with insulin allergy have been reported to be managed by CSII successfully [24,29,53,[57][58][59][60]. It has been proposed that combining CSII and the use of a rapid-acting insulin analogue would be a valuable strategy in the treatment of insulin allergy [6].…”

Section: Continuous Subcutaneous Insulin Infusion (Csii)mentioning

confidence: 99%